I 
119TH CONGRESS 
2D SESSION 
H. R. 7091 
To direct the Secretary of Veterans Affairs to establish an investigational 
research and extended access treatment program utilizing innovative 
treatments and emerging therapies to address conditions with unmet 
medical needs, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 15, 2026 
Mr. BERGMAN (for himself and Mr. CORREA) introduced the following bill; 
which was referred to the Committee on Veterans’ Affairs 
A BILL 
To direct the Secretary of Veterans Affairs to establish an 
investigational research and extended access treatment 
program utilizing innovative treatments and emerging 
therapies to address conditions with unmet medical 
needs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Expanding Veterans’ 
Access to Emerging Treatments Act’’. 
SEC. 2. SENSE OF CONGRESS. 
It is the sense of Congress that— 
VerDate Sep 11 2014 
17:51 Jan 27, 2026
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7091.IH
H7091
ssavage on LAPJG3WLY3PROD with BILLS
(1) Many conditions, such as chronic pain, post- 
traumatic stress disorder, and substance use dis-
orders, continue to challenge the veteran community 
amid a lack of new innovative treatments and 
emerging therapies. 
(2) These and other conditions represent an ur-
gent unmet medical need among veterans. 
(3) The Department of Veterans Affairs should 
continue to advance research and facilitate timely 
access to innovative treatments and emerging thera-
pies, including psychedelic- and entactogenic-assisted 
therapies, for veterans with such unmet treatment 
needs. 
SEC. 3. RESEARCH PROGRAM OF THE DEPARTMENT OF 
VETERANS AFFAIRS ON INNOVATIVE TREAT-
MENTS AND EMERGING THERAPIES FOR CER-
TAIN COVERED CONDITIONS. 
(a) ESTABLISHMENT.—Not later than 90 days after 
the date of enactment of this Act, the Secretary of Vet-
erans Affairs shall develop an investigational research pro-
gram for the treatment of veterans diagnosed with a cov-
ered condition using innovative treatments and emerging 
therapies, consistent with applicable Federal law, includ-
ing laws governing investigational medical products and 
controlled substances. Not later than 60 days after the 
VerDate Sep 11 2014 
17:51 Jan 27, 2026
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7091.IH
H7091
ssavage on LAPJG3WLY3PROD with BILLS
date of the enactment of this Act, the Secretary shall des-
ignate a lead administrator to carry out the research and 
treatment program under this section. 
(b) INVESTIGATIONAL RESEARCH PROGRAM.—The 
Department of Veterans Affairs may— 
(1) conduct one or more clinical trials for the 
treatment of a covered condition that include vet-
erans as participants in the clinical trial using inno-
vative treatments and emerging therapies, which 
may be selected following a review of their efficacy, 
safety, and ease of administration; and 
(2) develop a compassionate or extended access 
protocol that facilitates consideration of, and as ap-
propriate access to, innovative treatments and 
emerging therapies. 
(c) PARTICIPATION
IN CLINICAL TRIALS
OR EX-
TENDED ACCESS.—The Secretary shall establish a process 
under which a veteran diagnosed with a covered condition 
may— 
(1) participate in a clinical trial conducted 
under this section; or 
(2) be considered for access to an innovative 
treatment or emerging therapy under a compas-
sionate or extended access protocol, as clinically ap-
propriate. 
VerDate Sep 11 2014 
17:51 Jan 27, 2026
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7091.IH
H7091
ssavage on LAPJG3WLY3PROD with BILLS
(d) ADDITIONAL AUTHORITY.—In addition to car-
rying out the activities under this section, the Secretary 
may, using amounts otherwise authorized to be appro-
priated and otherwise available to the Department of Vet-
erans Affairs, support one or more clinical research trials 
using innovative treatments and emerging therapies de-
scribed in subsection (g). 
(e) REPORT REQUIRED.—Not later than one year 
after the date of the enactment of this Act, the Secretary 
shall submit to the Committees on Veterans’ Affairs of 
the House of Representatives and the Senate a report, in-
cluding the following: 
(1) Identification of clinics designated to host 
activities under such a protocol under this section 
and the number of veterans expected to participate 
in a clinical trial conducted in subsection (b); 
(2) Information on the findings and outcomes 
of such clinical trials, including preliminary out-
comes; and 
(3) A review of all innovative treatments and 
emerging therapies utilized for the treatment of cov-
ered conditions, including safety and efficacy stud-
ies, cost, regulatory, and logistical considerations as-
sociated with each. 
VerDate Sep 11 2014 
17:51 Jan 27, 2026
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7091.IH
H7091
ssavage on LAPJG3WLY3PROD with BILLS
(f) SUNSET.—Not later than two years after the date 
of enactment of this Act, the investigational program shall 
be reviewed by the Secretary of Veterans Affairs, who may 
then choose to extend or terminate the program at their 
discretion. 
(g) DEFINITIONS.—In this section: 
(1) The term ‘‘innovative treatment’’ means 
any of the following: 
(A) 3,4-Methylenedioxy-methamphetamine; 
(B) 5-Methoxy-N,N-dimethyltryptamine; 
(C) 5-Methoxy-2-aminoindane; 
(D) Ibogaine; 
(E) Ketamine; 
(F) Psilocybin; and 
(G) Such other treatments as may be des-
ignated by the Secretary. 
(2) The term ‘‘emerging therapies’’ means any 
of the following: 
(A) Investigational pharmaceutical can-
didates that meet the Government’s Definition 
of Recovery; 
(B) Investigational medical devices, such 
as deep brain neurostimulation or hyperbaric 
oxygen therapy; and 
VerDate Sep 11 2014 
17:51 Jan 27, 2026
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H7091.IH
H7091
ssavage on LAPJG3WLY3PROD with BILLS